New cardiovascular risk factors exist, but are they clinically useful?
Cardiology Division, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
Received 18 December 2007; accepted 20 December 2007.
* Corresponding author. Tel: +1 617 724 6158, Fax: +1 617 726 4105, Email: tjwang{at}partners.org
See page 436 for the editorial comment on this article (doi:10.1093/eurheartj/ehm566)
There is substantial interest in identifying new risk factors for cardiovascular disease, to improve our understanding of disease biology and to account for the cases of heart disease that cannot be explained by known risk factors. Investigation of putative risk factors frequently involves the study of circulating biomarkers. In recent years, a spirited debate has arisen regarding the validity and usefulness of these new measures. A careful assessment of the evidence suggests that most newer biomarkers are not ready for routine clinical use in the primary prevention setting. The good news is that traditional risk factors perform quite well with regard to the prediction of future cardiovascular risk. Inadequate recognition and control of the ‘classic’ risk factors continues to account for a large number of avoidable cardiovascular events. At the same time, new insights into disease mechanisms should lead to the development of novel preventive therapies, regardless of how well biomarkers themselves perform in risk stratification. Furthermore, state-of-the-art technologies that allow the profiling of large panels of genes, transcripts, proteins, or small molecules should facilitate the discovery of newer biomarkers capable of providing both mechanistic insight and true prognostic utility.
Key Words: Biomarkers • Risk factors • Cardiovascular disease • Prevention • C-reactive protein
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- New cardiovascular risk determinants do exist and are clinically useful
- Yvo M. Smulders, Abel Thijs, and Jos W. Twisk
EHJ 2008 29: 436-440.[Abstract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  R. E. Gerszten, F. Accurso, G. R. Bernard, R. M. Caprioli, E. W. Klee, G. G. Klee, I. Kullo, T. A. Laguna, F. P. Roth, M. Sabatine, et al. Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs Am J Physiol Lung Cell Mol Physiol, July 1, 2008; 295(1): L16 - L22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-J. Janket, Y. Shen, and A. E. Baird Why must new cardiovascular risk factors be carefully re-assessed prior to clinical application? Eur. Heart J., May 2, 2008; 29(10): 1336 - 1337. [Full Text] [PDF]
|
|
|
|
|
|
S. S. Levinson New cardiovascular risk determinants do exist and are clinically useful Eur. Heart J., May 2, 2008; 29(10): 1335 - 1335. [Full Text] [PDF]
|
|
|
|
|
|
Y. Smulders New cardiovascular risk determinants do exist and are clinically useful: reply Eur. Heart J., May 2, 2008; 29(10): 1335 - 1336. [Full Text] [PDF]
|
|